Today: 20.Apr.2021
(EANM, European Association of Nuclear Medicine) Austria Europe - Prostate cancer
Rate this item
(0 votes)

European Association of Nuclear Medicine: Prostate cancer patients who are resistant to hormone treatment used to have a poor prognosis. Until recently, the diagnostic and therapeutic possibilities had been limited, but now innovative developments in nuclear medicine imaging and therapy open up promising pathways. Novel substances used with PET/CT (positron-emission tomography combined with computed tomography) not only allow for better diagnosis but also offer treatment options where other therapies have failed.

Read 2747 times Last modified on Sunday, 03 May 2020 05:28